Editors-in-Chief

Emad Kandil, MD, FACS, FACE

Department of Surgery, Tulane University School of Medicine, New Orleans, LA, USA

Dr. Kandil is a Professor of Surgery, the Elias Hanna Endowed Chair in Surgery and the Chief of General, Endocrine and Oncological Surgery Division at Tulane University Medical School, New Orleans, LA. He is also a senior excutive member of Tulane cancer excutive council and the director of the clinical Endocrine Surgery Fellowship at Tulane.

He completed his training with a clinical fellowship in endocrine surgery at Johns Hopkins University School of Medicine. Dr. Kandil is a fellow of many prestigious societies including American Surgical Association, American College of Surgeons and the American Association of Clinical Endocrinologists. He serves on several national, international committees, and served on multiple institutional leadership positions including being the Chair of Tulane General Medical Faculty. Dr. Kandil Is the current presidnet of Surgical Association of Louisiana.

Dr. Kandil has written over 300 original articles, invited reviews and book chapters and served on numerous editorial boards. Dr. Kandil has special interest in robotic endocrine surgery and he has the largest experience in US with robotic thyroid and parathyroid surgery using different approaches. Additionally, Dr. Kandil has the largest experience in radiofrequency ablation of thyroid nodules in the country. He has lectured all over the world on topics related to endocrine surgery. Dr. Kandil received multiple national awards including the Shipley award by the Southern Surgical Association, in recognition of astute surgical scholarship. He is the founder of an annual national course on thyroid and parathyroid surgery – a program that is now in its 11th year. His research interests have focused on clinical outcome research related to endocrine surgery. His laboratory research focus is on identification of novel genetic markers for active surveillance and examining the anti-tumor efficacies of multiple pathways targeting thyroid cancer using in vitro and mouse-model cell in addition to human specimens.


Xi-ru Li, MD

Division of Breast Surgery, Department of General Surgery, General Hospital of Chinese, People's Liberation Army, Beijing, China

Dr. Li graduated from the Department of Clinical Medicine of the First Military Medical University in 1989 with a bachelor degree. He worked in the Department of General Surgery, Tang Du Hospital, Fourth Military Medical University, from 1989 to 2000, during which he received his master degree and was trained as attending physician and lecturer. He joined the Department of General Surgery of PLA General Hospital in September 2000. Currently he acts as the Deputy Executive Director of the Department of General Surgery and also is the Chief of the Department of Breast Surgery in PLA General Hospital.

He acts as a consultant for China National Drug and Food Administration new drug evaluation, vice Chairman of Military Breast and Endocrine Surgery Society, member of the Military General Surgery Society, member of Chinese Society of Clinical Oncology Breast Cancer Group, and member of Chinese Medical Doctor Association Breast Disease Group. He is the member of the editorial boards of several journals including Chinese Journal of Breast Disease.

He has published 60 plus papers in domestic and international journals. He has obtained a national invention patent. He is the responsible person for the following key research projects: "Application of Proteomics Technology in Predicting the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer" (MA245), supported by the “11th Five-Year Plan” Military Health Research Fund; "Application of FISH Technology for the Detection of Breast Cancer HER-2 Gene (2007)", supported by the Ministry of Health; "Application of Magnetic Resonance Image Reconstruction and Simulated Surgery in the Breast-conserving Surgery for Patients with Breast Cancer - Breast Precision Surgical Technology" (2010gxjs092), supported by the Military Clinical High-Tech Key Program; and "Application of iTRAQ Proteomics Technology in Analyzing the Changes of the Protein Expressions after Neoadjuvant Chemotherapy for Breast Cancer" (2011), supported by the National Natural Science Fund. Meanwhile, he has participated in many other studies supported by the National "973 Program", "863 Program", and Beijing Municipal Key Program. He has co-authored several books.

He has accumulated rich experiences in medical care, teaching, and relevant research in the past two decades. Under his leadership, a multi-discipline team, known as "Breast Disease Diagnosis and Treatment Cooperative Team of PLA General Hospital" and participated by the Department of Surgery, Department of Oncology, Department of Pathology, Department of Radiotherapy, Dpartment of Ultrasound, Mammography room, and MRI room, has been established. Doctors who are involved in the management of breast diseases from different departments participate in this team and conduct academic activities regularly. Dr. Li has rich experiences in the early screening, etiological analysis, and clinical treatment of breast tumors. He plays a leading role in the management of clinically non-palpable breast cancer in China and keeps close contact with his international colleagues. He introduced the technique of magnetic resonance (MR)-guided biopsy into China and pioneered the application of intra-operative radiotherapy in the breast-conserving surgery for patients with breast cancer. He is also actively involved in the introduction of sentinel lymph node biopsy, phase I and phase II breast reconstruction after surgery for breast cancer, mastectomy (SSM) with conservation of the nipple-areola complex, implants reconstruction, and Mammotome minimally invasive breast surgery. Furthermore, he has standardized the multi-discipline breast-conserving treatment procedures, established a DNA bank for patients with breast cancer, and conducted pre-clinical and clinical research on pharmacogenomics-guided individualized treatment for breast cancer.